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Stem Cell Research (2012) 9, 277–283Five years of Stem Cell Research —
Reflections on progress in the fieldStem Cell Research has reached the significant milestone
of five years in publication and, as Editor-in-Chief, I would
like to thank our publisher, Elsevier, the journal editors and
our reviewers for their hard work, dedication and support in
launching and establishing a new journal in the stem cell
field. Most of all, I would like to thank the authors who
entrusted their precious manuscripts to us. I have been
privileged to be the founding editor, and along with
Christine Mummery, the deputy Editor-in-Chief, and the
associate editors Markus Grompe, Paul Simmons, Pam Robey
and, most recently, Paolo Bianco and Paul Gadue, we are
justly proud of the achievements of Stem Cell Research and
the impact factor of 5.2 that it has recently received.
We would like to mark this occasion by reflecting on
some of the amazing developments in our field that we
have been privileged to witness and participate in. We
have assembled short vignettes contributed by members
of the scientific community in which they have recounted
their personal views on key discoveries that they feel have
shaped stem cell research over the past five to ten years.
Whilst authors were encouraged to refer to their own
work, some have chosen to also highlight publications
from others in their field whilst others wished to make
more general observations. Their comments are
reproduced essentially as received, with minimal editing.
We hope that you find them interesting, insightful and
stimulating!
Andrew Elefanty
Editor-in-Chief
Stem Cell Research
International Society for Stem Cell Research
Lisa Kamen and Nancy Witty
ISSCR Headquarters, 5215 Old Orchard Road, Suite 270 Skokie, IL
60077, USA
The global sharing of knowledge has been crucial to the
rapid advancement of stem cell research, from its roots in
developmental biology to the discovery of induced1873-5061/$ - see front matter © 2012 Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.scr.2012.10.001Pluripotent Stem Cells (iPSCs) and reprogramming. Since its
inception in 2002, the International Society for Stem Cell
Research (ISSCR) has provided a global forum for the
exchange of information, bringing together a dynamic and
international community of researchers.
The growing ISSCR membership, 40% of which are junior
investigators, is a vibrant mix of stem cell research pro-
fessionals representing 57 countries. The ISSCR's annual
meeting series continues to expand with programming
reflective of the ever-evolving nature of stem cell research.
Our global Conference Series was designed to further
support our worldwide membership.
The ISSCR has become a voice for the stem cell
community, providing professional guidelines, public educa-
tion and advocacy. We are pleased to support the growth of
this dynamic field and to act as a catalyst in bringing stem
cell advances and ideas to the world stage. The ISSCR
continues its commitment to and support of the field as it
moves ever closer to realizing the potential of stem cells and
their clinical applications.
Tissue specific stem cell research
Stem cells in the intestinal crypts
Hans Clevers
Hubrecht Institute, KNAW and University Medical Center
Utrecht,
Uppsalalaan 8, 3584CT Utrecht, the Netherlands
The intestinal epithelium is the fastest self-renewing
tissue of mammals, turning-over in less than a week. C.P.
Leblond postulated over 5 decades ago that small cycling
cells at the crypt base represented the stem cells fueling
this intense self-renewal process (1). In 2007, we reported
that Lgr5 marks these cells and could formally prove their
‘stemness’ by lineage tracing after creating Lgr5-knockin
mouse models (2). Paneth cells that are intermingled with
the Lgr5 stem cells provide essential stem cell growth
signals. It has since become possible to isolate single Lgr5
stem cells from adult mouse and human intestines and
expand these in culture over long periods of time. The
278resulting ‘mini-guts’ can be transplanted safely into
recipient mice.
1. B. Messier and C.P. Leblond. Cell proliferation and
migration as revealed by radioautography after injection of
thymidine-H3 into male rats and mice. Am J Anat 106, 247–285,
1960.
2. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M,
Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ and
Clevers H. Identification of stem cells in small intestine and colon
by marker gene Lgr5. Nature 449, 1003–7, 2007.
Stem cells of the mammary gland
Jane Visvader
Australian Cancer Research Foundation
Division of Stem Cells and Cancer, Walter and Eliza
Hall Institute, 1G Royal Parade, Parkville 3052, Victoria, Australia
Early studies demonstrated that any portion of a mouse
mammary ductal tree could recapitulate an entire mammary
gland upon transplantation indicating the presence of stem
cells. In 2006, mammary stem cells were prospectively
identified and isolated (1,2) through in vivo mammary
reconstitution experiments. Indeed, a single mammary
stem cell had the potential to fully reconstitute a mammary
gland, representing the first demonstration that an epithe-
lial organ could be regenerated at the single cell level (1).
This discovery, along with the identification of other
committed progenitors with limited proliferation capacity,
has indicated that the mammary epithelium is organized in a
hierarchical manner. The identification of this hierarchy is a
key development in mammary biology and has paved the way
for understanding the role of these cells in both normal
development and neoplasia. Finally, these studies hold the
promise of leading to therapeutic strategies that target
specific mammary cell subtypes.
1. Mark Shackleton, François Vaillant, Kaylene J. Simpson, John
Stingl, Gordon K. Smyth, Marie-Liesse Asselin-Labat, Li Wu,
Geoffrey J. Lindeman & Jane E. Visvader. Generation of a
functional mammary gland from a single stem cell. Nature 439,
84–88, 2006.
2. John Stingl, Peter Eirew, Ian Ricketson, Mark Shackleton,
François Vaillant, David Choi, Haiyan I. Li & Connie J. Eaves.
Purification and unique properties of mammary epithelial stem
cells. Nature 439, 993–997, 2006.
The long and arduous quest for the development of
cellular therapies using tissue specific mesenchymal stem
cells
Stan Gronthos
Mesenchymal Stem cell Group, Department of Haematology, SA
Pathology,
Frome Road, Adelaide 5000, South Australia and
Centre for Stem Cell Research,
Robinson Institute, University of Adelaide, South Australia
Pioneering studies performed in the laboratories of
Alexander Friedenstein and Maureen Owen helped develop
the concept of a stromal hierarchy of cellular differentia-
tion within the bone marrow microenvironment responsible
for the support of hematopoiesis and skeletal tissue
regeneration. These studies laid the foundation for ourresearch group, and those of others, to develop unique
reagents to identify purified preparations of multi-potential
bone marrow stromal precursor cells or mesenchymal stem
cells (MSC). Similar strategies were subsequently
employed to identify MSC-like populations in different
tissues over the last two decades. Numerous pre-clinical
studies and early human trials have provided strong
evidence to support the use of tissue specific MSC-like
populations for cellular-based engineering to repair
defective or damaged connective tissues such as bone
and to a lesser extent cartilage, ligament, muscle,
tendon, dentine and cementum. Of note, MSC-like
populations also demonstrate an immune privilege qual-
ity with the capacity to regulate inflammatory responses
via direct cell–cell interactions and through the produc-
tion of paracrine factors. These findings have now
opened up the possibility for the clinical use of
allogeneic MSC preparations without the consequences
of immune rejection from the host. It is now anticipated
that within the next decade, different allogeneic tissue
specific MSC will be utilized for a wider range of clinical
problems including, autoimmune and inflammatory based
diseases, adjunct cancer therapy, cardiovascular dis-
ease, neurological conditions and solid organ transplan-
tation.
Adipose tissue as a source of cells for regenerative
medicine
Jeff Gimble MD PhD
Stem Cell Biology laboratory
Pennington Biomedical Research Center
Baton Rouge, Louisiana 70808, USA.
During the past decade, international efforts by multiple
independent laboratories have advanced the use of adipose
tissue as a regenerative cell source. Two areas highlight the
tissue engineering potential of adipose-derived stromal/
stem cells (ASCs). First, basic science studies have
documented the adipogenic potential of ASCs in vitro and
in animal models. Based on favorable outcomes, plastic
surgeons in have begun to develop data supporting the
safety and benefits of ASC to improve fat grafting and soft
tissue reconstruction in clinical settings. Second, in vitro
and animal studies have documented the ASC's osteogenic
potential. Craniofacial surgeons have used autologous ASC
in combination with biomaterial scaffolds and BMP2 to
repair hard palate defects secondary to cancer treatment.
Together, these pioneering studies suggest that ASC can be
used for bone and soft tissue regeneration, thereby setting
the stage for randomized, controlled clinical trials in the
near future.
Skeletal (‘mesenchymal’) stem cells and the hemato-
poietic niche
Paolo Bianco
Stem Cell Laboratory, Biomedical Science Park San Raffaele and
Department of Experimental Medicine and Pathology
La Sapienza University, Rome, Italy
The idea of a stem cell for multiple skeletal tissues in the
mammalian BM (later to be rephrased and distorted in the
current ‘MSC’ concept) was only partially substantiated
279experimentally since the times of the pioneering work of
Alexander Friedenstein. While the existence of an assayable
multipotent progenitor had been solidly proven, the ability
of such a progenitor to self-renew in vivo remained to be
determined. Likewise, the in vivo identity of cells
explanted as bone marrow clonogenic progenitors had
remained elusive. It has now been established that in
humans, clonogenic stromal progenitors (‘mesenchymal’
stem cells) reside at the abluminal surface of bone
marrow sinusoids. These cells are not only multipotent,
but can reestablish (upon in vivo transplantation) a
compartment of perisinusoidal, clonogenic stromal cells
that can be serially passaged and transplanted, and thus
represent self-renewing, bona fide stem cells. These
cells establish and transfer the HSC microenvironment/
niche in vivo, which makes the sinusoidal wall the site of
coexistence of two interacting systems of stem cells
(hematopoietic and stromal/‘mesenchymal’). These data
will now permit dissection of the nature and ontogeny
of perivascular progenitors in bone marrow and else-
where, and to probe the HSC ‘niche’ effect in humans
in vivo.
1. B. Sacchetti, A. Funari, S. Michienzi, S. Di Cesare, S.
Piersanti, I. Saggio, E. Tagliafico, S. Ferrari, P.G. Robey, M.
Riminucci, P. Bianco, Self-Renewing Osteoprogenitors in Bone
Marrow Sinusoids Can Organize a Hematopoietic Microenvironment,
Cell, 131 (2007) 324–336.
2. P. Bianco, P.G. Robey, P.J. Simmons, Mesenchymal stem cells:
revisiting history, concepts, and assays, Cell Stem Cell, 2 (2008)
313–319.
3. P. Bianco. Bone and the hematopoietic niche: a tale of two
stem cells, Blood, 117 (2011) 5281–5288.Hematopoietic stem cells and their niche
Hiromitsu Nakauchi, M.D., Ph.D.
Director, Center for Stem Cell Biology and Regenerative
Medicine,
The Institute of Medical Science, The University of Tokyo
Minato-ku, Tokyo 108-8639, Japan
Advancements in multicolor analysis and cell sorting have
contributed to the study of hematopoietic stem cells (HSCs),
such as enabling their prospective isolation in highly purified
form for in vivo clonal analysis. Further clonal and
quantitative measurement of repopulating abilities revealed
unexpected heterogeneity and hierarchy even in the most
primitive HSC compartment. Slow and low-level engraft-
ment in primary recipients can become robust in secondary
recipients. Such slow engrafting and rarely dividing HSCs can
be detected by label-retaining but not conventional assays.
Therefore the definition of HSCs needs to be revised along
with the development of a novel assay system covering a
wider range of HSC activity.
On the other hand, the development of various image
analysis and conditional gene targeting systems have
newly identified glial cells as a member of the HSC
niche. This is in addition to the initial osteoblastic and
endothelial/perivascular cells, mesenchymal cells and
macrophages. Interestingly HSCs, as maintained by glial
cells, uses the same mechanisms as C. elegans to
hibernate in the BM. Since the BM niche regulates HSCsand possibly even leukemic stem cells, it has important
clinical implication and provides a potential pharmaceu-
tical target. Nonetheless, the BM niche remains ill defined
in its structure, location and function and requires further
studies.
A decade of discovery in cardiac stem cells
Richard P. Harvey
Victor Chang Cardiac Research Institute, Darlinghurst 2010,
Australia and
St. Vincent's Clinical School, University of New South Wales,
Kensington 2052, Australia
Since the birth of the field around a decade ago (1),
the science of cardiac stem cells and heart repair
continues to be rich and diverse. Driven forward by
clinical imperatives, the demonstration that various
progenitor populations can transdifferentiate into
cardiomyocytes provided a rationale for stem cell
therapies for heart disease (2). Clinical trials of bone
marrow cell therapies have lead the way and shown
improvements, albeit modest, in clinical endpoints (3).
More recently, phase I trials using the now well
characterised cardiac ckit+ stem cells or their
derivative “cardiospheres”, are also significant mile-
stones (4,5). However, as in animal studies (5), the
mechanisms of benefit remain unclear. The robust
facultative regeneration of the zebrafish myocardium
after surgical injury we now know occurs via dediffer-
entiation and proliferation of existing cardiomyocytes
(6,7). Strikingly, such regeneration can also occur in
mammalian hearts, but only during a brief window of
cardiomyocyte proliferative competence in neonates,
after which collagen scarring predominates (8). None-
theless, ways have been found to stimulate a degree of
cardiomyocyte proliferation in the adult (9–11).
Cardiomyocyte replacement in homeostasis and/or
disease in mouse and human hearts has been demon-
strated, but its degree is still being debated, with
results differing wildly between studies, from little or
none, to many-fold (12–14). The adult epicardium is
also emerging as a significant player in heart repair —
after injury its developmental transcriptional program
is reactivated (15) and it contributes new fibroblasts
and perivascular cells to the injury site (16,17), and if
stimulated some cardiomyocytes (18). Developmental
biology has also made strong contributions, with a
second heart progenitor field mapped in the embryo
(19) with possible preservation of some of these
progenitors for a time in a myocardial niche, and the
demonstration that defects in second field progenitor
cell behavior underlies congenital heart disease. Also,
the developing epicardium was recently shown to seed
the adult myocardial interstitium with MSC-like stem
cells (20). There has been progress in augmenting the
differentiation of ES/iPS cell into cardiac lineages for
therapies, tissue engineering and drug screening, including
methods for iPS cell derivation, expansion and differenti-
ation in suspension culture (21,22). However, the relatively
new science of somatic cell reprogramming is poised to
offer us yet new directions for heart repair, with recent
280findings that direct reprogramming of cardiac fibroblasts
into cardiomyocytes in infarcted mouse hearts using but a
few cardiac developmental transcription factors confers
functional benefit (23,24).
1. Leri, A., Kajstura, J. & Anversa, P. Cardiac stem cells and
mechanisms of myocardial regeneration. Physiological Reviews 85,
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regeneration by gata4(+) cardiomyocytes. Nature 464, 601–605 (2010).
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606–609 (2010).
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tion. Cell 127, 607–619 (2006).
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22. Kattman, S. J., Huber, T. L. & Keller, G. M. Multipotent Flk-1+
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What have I learned in the past five years?
Eduardo Marbán, MD, PhD
Mark S. Siegel Family Professor and Director,
Cedars-Sinai Heart Institute
Cedars-Sinai Medical Center
Los Angeles, CA 90048, USA
Cardiologists have been attempting to achieve heart
regeneration for more than a decade, but, I believe,
focusing on the wrong endpoints. Most clinical trials have
used contrast ventriculography or echocardiography to
gauge ejection fraction (EF). EF is a global nonspecific
measure of heart function that is easy to measure, but
does not assess regeneration. In order to document the
latter, it is vital to demonstrate an increase in living heart
mass as a result of therapy, in a rigorously controlled
manner.
Therapeutic regeneration is indeed possible. In our
CADUCEUS study, published earlier this year in The Lancet,
we showed an increase in living heart muscle mass in heart
attack victims treated with heart-derived cells (1).
Concurrently, scar mass decreased. Control subjects had
no such changes. These observations fundamentally alter
the way that we approach heart disease: what was thought
to be irreversible injury may now be reversible by cell
therapy.
The mechanisms of regeneration are indirect. Five years
ago, we assumed that transplanted cells would work by
engrafting, proliferating and differentiating. We now know
that such is not the case: instead, transplanted cells activate
endogenous repair pathways, such that the new tissue
generated is of host origin rather than a direct outgrowth
of the transplanted cells.
Our goals in regenerative medicine are more ambitious
than ever, and now seem within reach.
(1) Raj R Makkar, Rachel R Smith, Ke Cheng, Konstantinos
Malliaras, Louise EJ Thomson, Daniel Berman, Lawrence SC
Czer, Linda Marbán, Adam Mendizabal, Peter V Johnston,
Stuart D Russell, Karl H Schuleri, Albert C Lardo, Gary
Gerstenblith, Eduardo Marbán. Intracoronary
cardiosphere-derived cells for heart regeneration after
myocardial infarction (CADUCEUS): a prospective,
randomised phase 1 trial. The Lancet, 379, 895–904, 2012.
Pluripotent cells and reprogramming
“Organ in a dish”
Nadav Sharon and Nissim Benvenisty
Stem Cell Unit, Department of Genetics, The Hebrew University,
Jerusalem, Israel
Embryonic stem cells (ESCs) may differentiate into
virtually any cell type. An inspiring challenge is to utilize
ESCs for the generation of complex tissues, or even entire
organs in vitro. This, however, requires the timed
281activation of numerous molecular signals, most of which
are still far from elucidation. Yet, recent advancements
make the generation of an “organ in a dish” seem closer
than ever. A remarkable breakthrough was achieved when
ESCs were differentiated in 3D into a cortex like structure,
in which the different cell types were ordered as in the
brain (1). A similar technique was used to generate the
optic cup and adenohypophysis, both of which contained
the various cell types of these naturally forming organs
(2,3). Interestingly, the cells in these structures were
patterned in accordance with the forming retina and
Rathke's pouch. Similar results were obtained when
intestinal ‘organoids’ formed in vitro resembled the
polarized, columnar epithelium of the intestine, including
its characteristic villi and crypts (4). In an attempt to
achieve a more general control over the formation of
complex structures, ESCs were recently differentiated into
human gastrula organizer cells, the cells which establish
the initial embryonic body plan (5). When injected into
frog embryos, these cells were able to induce a secondary
neural tube. Thus, it was shown that ESCs can form both
complex tissues, and comprise the basic mechanisms which
pattern the embryo and shape it. Hopefully, a combination
of self forming tissues and organizing structures derived
from human ESCs will allow the formation of elaborate
physiological organs.
1. Eiraku, M., Watanabe, K., Matsuo-Takasaki, M., Kawada, M.,
Yonemura, S., Matsumura, M., Wataya, T., Nishiyama, A.,
Muguruma, K. and Sasai, Y. Self-organized formation of polarized
cortical tissues from ESCs and its active manipulation by extrinsic
signals. Cell Stem Cell, 3, 519–532, 2008.
2. Eiraku, M., Takata, N., Ishibashi, H., Kawada, M., Sakakura,
E., Okuda, S., Sekiguchi, K., Adachi, T. and Sasai, Y. Self-organizing
optic-cup morphogenesis in three-dimensional culture. Nature,
472, 51–56, 2011.
3. Suga, H., Kadoshima, T., Minaguchi, M., Ohgushi, M., Soen,
M., Nakano, T., Takata, N., Wataya, T., Muguruma, K., Miyoshi, H.,
Yonemura, S., Oiso, Y. and Sasai, Y. Self-formation of functional
adenohypophysis in three-dimensional culture. Nature, 480, 57–62,
2011.
4. Spence, J.R., Mayhew, C.N., Rankin, S.A., Kuhar, M.F.,
Vallance, J.E., Tolle, K., Hoskins, E.E.,
Kalinichenko, V.V., Wells, S.I., Zorn, A.M., Shroyer, N.F. and
Wells, J.M. Directed differentiation of human pluripotent stem
cells into intestinal tissue in vitro. Nature, 470, 105–109, 2011.
5. Sharon, N., Mor, I., Golan-lev, T., Fainsod, A. and Benvenisty,
N. Molecular and functional characterizations of gastrula organizer
cells derived from human embryonic stem cells. Stem Cells, 29,
600–608, 2011.
Reprogramming somatic cells to pluripotency
Jose Polo
Monash Immunology and Stem Cell Laboratories and
Australian Regenerative Medicine Institute
Monash University, Wellington Road, Clayton 3800, Victoria,
Australia
Seminal work by Takahashi and Yamanka in 2006
demonstrated that retroviral overexpression of the tran-
scription factors Oct4, Sox2, c-Myc and Klf4 was sufficient to
reprogram somatic cells into a pluripotent state, giving rise
to induced pluripotent stem (iPS) cells (1). During the
following years, iPS cells have been derived from manydifferent cell types and have proven to be similar, if not
identical, to ES cells, sharing the same developmental and
differentiation potential (2). Several groups have shown that
iPS cells can be derived using different combinations of
transcription factors and by several transducing methods,
including integration-free systems. During reprogramming,
the epigenome of the somatic cell is reset into an embryonic
stem cell (ES) state, however recent work demonstrated
retention of an epigenomic memory from the cell of origin
which may have an impact on downstream applications
(3,4). The future of the field is promising with
patient-specific iPS cells already in use in different plat-
forms for disease modelling and with two clinical trials due
to begin in the next year. Further understanding of the
molecular events taking place during reprogramming will
ensure this technology moves safely forward in the field of
regenerative medicine.
1. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem
cells from mouse embryonic and adult fibroblast cultures by
defined factors. Cell 126, 663–676, 2006.
2. Stadtfeld, M. & Hochedlinger, K. Induced pluripotency:
history, mechanisms, and applications. Genes Dev 24, 2239–2263,
2010.
3. Maherali, N. et al. Directly reprogrammed fibroblasts show
global epigenetic remodeling and widespread tissue contribution.
Cell Stem Cell 1, 55–70, 2007.
4. Polo, J. M. et al. Cell type of origin influences the molecular
and functional properties of mouse induced pluripotent stem cells.
Nat Biotechnol 28, 848–855, 2010.
Transdifferentiation by single transcription factors
Thomas Graf
ICREA Professor and Coordinator,
Gene Regulation, Stem Cells and Cancer Program
Center for Genomic Regulation, CRG
E 08003 Barcelona, Spain
Over the past decade my laboratory has discovered that
fully differentiated cells could be induced to
transdifferentiate with single transcription factors at
extremely high efficiencies. We achieved this by the forced
expression of C/EBPalpha in both B cell precursors and
antibody-producing B cells, resulting in macrophages
exhibiting phagocytic capacity and other macrophage
specific characteristics (1). Furthermore, C/EBPalpha
induced the transdifferentiation of pre-T cells into macro-
phages (2) and a conversion of fibroblasts into
macrophage-like cells when co-expressed with its partner,
PU.1 (3). Finally, we developed a robust inducible pre-B
cell system (4) and showed that the switching into
macrophages is essentially direct, not involving
retro-differentiation (5). Because of its simplicity and
efficiency, this system is uniquely suited to elucidate the
molecular basis of transdifferentiation. We have also
written a review that outlines the principles of cell fate
choices (6) and another about the history of
transdifferentiation and cell reprogramming (7).
1. Xie H, Ye M, Feng R, & Graf T (2004) Stepwise reprogramming
of B cells into macrophages. Cell 117(5):663–676.
2. Laiosa CV, Stadtfeld M, Xie H, de Andres-Aguayo L, & Graf T
(2006) Reprogramming of committed T cell progenitors to macro-
phages and dendritic cells by C/EBP alpha and PU.1 transcription
factors. Immunity 25(5):731–744.
2823. Feng R, et al. (2008) PU.1 and C/EBPalpha/beta convert
fibroblasts into macrophage-like cells. Proceedings of the National
Academy of Sciences of the United States of America 105(16):6057–
6062.
4. Bussmann LH, et al. (2009) A robust and highly efficient
immune cell reprogramming system. Cell Stem Cell 5(5):554–566.
5. Di Tullio A, Vu Manh TP, Schubert A, Mansson R, & Graf T
(2011) CCAAT/enhancer binding protein alpha (C/
EBP(alpha))-induced transdifferentiation of pre-B cells into macro-
phages involves no overt retrodifferentiation. Proceedings of the
National Academy of Sciences of the United States of America
108(41):17016–17021.
6. Graf T & Enver T (2009) Forcing cells to change lineages.
Nature 462(7273):587–594.
7. Graf T (2011) Historical origins of transdifferentiation and
reprogramming. Cell Stem Cell 9(6):504–516.
Searching for hematopoietic stem cells
Andrew Elefanty
Murdoch Childrens Research Institute, The Royal Children's
Hospital, Parkville 3052, and MISCL, Monash University, Clayton
3800, Victoria, Australia
One of the most fascinating areas in science for me over
the past five to ten years has been the identification and
characterization of the earliest embryonic human hemato-
poietic stem cells and the struggle to identify and grow
similar cells from pluripotent stem cells in vitro. Success in
this latter endeavor would open the door for a range of cell
replacement therapies for hematological diseases. The
demonstration that cells from the Aorta–Gonad–Mesoneph-
ros of early human embryos could reconstitute immunode-
ficient mice by the laboratory of Alexander Medvinsky (1)
built on decades of research into early avian and murine
developmental hematopoiesis from many laboratories in-
cluding those of Medvinsky, Dzierzak, Cumano, Godin,
Nishikawa, Jaffredo, Pardanaud, Le Douarin and
Dieterlen-Lievre (2). This work was complemented by
important studies on the isolation of hematopoietic stem
cells from human umbilical cord blood by the laboratories of
John Dick and others (3,4). These key insights into
mammalian developmental hematopoiesis have provided
the necessary backdrop that informs the hunt to generate
hematopoietic stem cells from pluripotent stem cells. Whilst
this task has proved to be rather tricky and still elusive,
headway is being made. The laboratory of Gordon Keller first
isolated blast colony forming cells from human embryonic
stem cells (5), recapitulating their earlier findings in mouse
embryonic stem cells. Researchers have reported the
generation of lymphoid cells from human pluripotent cells
(6) and it will hopefully only be a matter of time before
repopulating hematopoietic stem cells can be generated
from pluripotent stem cells, or alternatively, directly
reprogrammed from somatic cells (7).
1. Ivanovs A, Rybtsov S, Welch L, Anderson RA, Turner ML,
Medvinsky A. Highly potent human hematopoietic stem cells first
emerge in the intraembryonic aorta-gonad-mesonephros region. J
Exp Med. 2011 Nov 21;208(12):2417–27.
2. Dieterlen-Lièvre F. The quest for hematopoietic stem cells in
the embryo. An interview with Françoise Dieterlen-Lièvre by
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The heart of the matter: cardiomyocytes from human
pluripotent stem cells
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A little over a decade ago, the first beating
cardiomyocytes were observed in aggregates of human
embryonic stem cells. Pluripotent stem cells had been
isolated from human blastocysts a couple of years earlier
but making ‘embryoid bodies’ from human embryonic stem
cells that could then differentiate spontaneously to heart
cells had proven not nearly as easy as in mice. The cells
would not stick together well in suspension and even died if
dissociated to single cells. Partial dissociation was the only
option and even then, Kehat et al. (1) reported that only 8%
of the aggregates formed in this way started to beat and,
within those aggregates, only a few cells were actually
cardiomyocytes. Our group tried to mimic development and
grew cell “pieces”, cut from the tight colonies of
undifferentiated cells, in co-culture with visceral endoderm
cells, rather like those adjacent to the developing heart. We
obtained cultures in which about 35% of the aggregates were
beating (2) but it was only when we left the fetal calf serum
out of the culture medium, that we obtained cultures with
more than 5% cardiomyocytes (3). This was easily enough
cardiomyocytes for their characterization by electrophysiol-
ogy and imaging, but hardly sufficient for studies
transplanting them into the hearts of animals after myocar-
dial infarction. Five years after cardiomyocytes were first
observed in culture, their use in treatment of myocardial
infarction became the major goal, even though more than
100 million cells would be needed to integrate into the
damaged heart to replace the lost tissue. This goal was the
main driver behind the efforts to improve differentiation
protocols and obtain efficient conversion of the
undifferentiated cells into cardiomyocytes.
Mimicking development of the heart in the embryo
proved the way to go. In the following years, Keller, Murry,
Elefanty, Stanley, Pedersen and others established pro-
tocols, based on factors like activin, bone morphogenetic
proteins and wnts, firstly to induce nascent mesoderm, then
pattern this mesoderm to form cardiac progenitors and
cardiomyocytes, just as in the embryo. If these factors are
283added to chemically defined medium at the correct relative
concentrations, many embryonic stem cell lines will now
form differentiated cultures with up to 70–80%
cardiomyocytes. This is light years away from our start. We
are not there yet though. These protocols still do not work
for all cell lines and the undifferentiated cell cultures may
need some kind of adaption to fit the subsequent differen-
tiation protocol. Ask any stem cell biologist in this area if
they would like a better protocol and nearly all will say yes.
In addition, we now have human induced pluripotent stem
cells. Whilst the dream of transplanting stem cell-derived
cardiomyocytes to cure the heart has actually moved rather
further away as we have begun to understand the challenges
ahead (4), a new paradigm has appeared on the horizon that
perhaps has a greater potential for treating heart com-
plaints. These are disease human iPS cells generated from
patients with inherited cardiac maladies or predispositions
to adverse physiological or pathological responses. The stem
cell-derived cardiomyocyte may soon be regarded as the
new heart patient, a “cure” for the cell being a potential
clinical remedy. New challenges ahead, though, even for this
more modest goal. The new differentiation protocols should
soon make it possible to derive cardiomyocytes efficiently
from human iPS cells, but it will not solve the problem that
the cardiomyocytes are still immature. They may not show
the disease phenotypes that the cardiologist observes in the
patient or the same responses as an adult cardiomyocyte to
stress and drugs. How, then, to develop a screen for drug
discovery? Or ways of detecting side effects of new drugs on
the heart? A new challenge for the next decade.
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epithelium — A new therapy for macular degeneration?
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Over the preceding decade, the possibility of replacing
cells lost as a consequence of retinal disease is fast
becoming a clinical reality. The loss of vision results fromdeath or irreversible damage to the retinal pigment
epithelium (RPE) and photoreceptors (1). Replacement of
RPE cells (2) or their translocation from the peripheral retina
is a viable treatment for age-related macular degeneration
(AMD), if surgical intervention occurs at an appropriate time
(3).
Human embryonic stem cells (HESCs) are pluripotent
cells derived from the inner cell mass of the embryonic
blastocyst (4). We, and others, have shown that HESCs have
the capacity to differentiate into RPE cells (5–7) and
photoreceptor progenitors (8–11). As such, HESCs have the
potential to supply RPE, and photoreceptors for the
treatment of AMD. Clinical trials using embryonic
stem-cell derived RPE as a therapeutic treatment for AMD
have commenced (12).
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